Cargando…
Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?
The aim of our research was to determine the use of CA125 and HE4 as prognostic factors in patients with different clinical staging of endometrial cancer. Sixty-two patients with advanced endometrial cancer and 287 patients with early stage endometrial cancer participated in the study. Based on the...
Autores principales: | Cymbaluk-Płoska, Aneta, Gargulińska, Paula, Bulsa, Michał, Kwiatkowski, Sebastian, Chudecka-Głaz, Anita, Michalczyk, Kaja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065496/ https://www.ncbi.nlm.nih.gov/pubmed/33807168 http://dx.doi.org/10.3390/diagnostics11040626 |
Ejemplares similares
-
The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2020) -
Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016) -
Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018) -
Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2017) -
Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2017)